FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046269364> ?p ?o ?g. }

• W2046269364 endingPage "e23080" @default.
• W2046269364 startingPage "e23080" @default.
• W2046269364 abstract "We performed a Phase I clinical trial from October 2007 to October 2009, enrolling patients affected by refractory solid tumors, to determine the maximum tolerated dose (MTD) of interleukin (IL)-2 combined with low dose cyclophosphamide (CTX) and imatinib mesylate (IM). In a companion paper published in this issue of OncoImmunology, we show that the MTD of IL-2 is 6 MIU/day for 5 consecutive days, and that IL-2 increases the impregnation of both IM and of its main metabolite, CGP74588. Among the secondary objectives, we wanted to determine immunological markers that might be associated with progression-free survival (PFS) and/or overall survival (OS). The combination therapy markedly reduced the absolute counts of B, CD4+ T and CD8+ T cells in a manner that was proportional to IL-2 dose. There was a slight (less than 2-fold) increase in the proportion of regulatory T cells (Tregs) among CD4+ T cells in response to IM plus IL-2. The natural killer (NK)-cell compartment was activated, exhibiting a significant upregulation of HLA-DR, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and CD56. The abundance of HLA-DR+ NK cells after one course of combination therapy positively correlated with both PFS and OS. The IL-2-induced rise of the CD4+:CD8+ T-cell ratio calculated after the first cycle of treatment was also positively associated with OS. Overall, the combination of IM and IL-2 promoted the rapid expansion of HLA-DR+ NK cells and increased the CD4+:CD8+ T-cell ratio, both being associated with clinical benefits. This combinatorial regimen warrants further investigation in Phase II clinical trials, possibly in patients affected by gastrointestinal stromal tumors, a setting in which T and NK cells may play an important therapeutic role." @default.
• W2046269364 created "2016-06-24" @default.
• W2046269364 creator A5000473619 @default.
• W2046269364 creator A5001102421 @default.
• W2046269364 creator A5012214419 @default.
• W2046269364 creator A5013335730 @default.
• W2046269364 creator A5013921145 @default.
• W2046269364 creator A5021624793 @default.
• W2046269364 creator A5024902665 @default.
• W2046269364 creator A5031362151 @default.
• W2046269364 creator A5039850863 @default.
• W2046269364 creator A5042558055 @default.
• W2046269364 creator A5044456322 @default.
• W2046269364 creator A5052579165 @default.
• W2046269364 creator A5056132643 @default.
• W2046269364 creator A5057516732 @default.
• W2046269364 creator A5070881504 @default.
• W2046269364 creator A5074612242 @default.
• W2046269364 date "2013-02-01" @default.
• W2046269364 modified "2023-09-26" @default.
• W2046269364 title "Phase I clinical trial combining imatinib mesylate and IL-2" @default.
• W2046269364 cites W1509384822 @default.
• W2046269364 cites W1555615616 @default.
• W2046269364 cites W1625919546 @default.
• W2046269364 cites W1964703707 @default.
• W2046269364 cites W1971993874 @default.
• W2046269364 cites W1973091654 @default.
• W2046269364 cites W1998739054 @default.
• W2046269364 cites W1998794592 @default.
• W2046269364 cites W1998870570 @default.
• W2046269364 cites W1998957717 @default.
• W2046269364 cites W2006215283 @default.
• W2046269364 cites W2015015957 @default.
• W2046269364 cites W2016086822 @default.
• W2046269364 cites W2031597713 @default.
• W2046269364 cites W2044253211 @default.
• W2046269364 cites W2045556155 @default.
• W2046269364 cites W2052753304 @default.
• W2046269364 cites W2055996134 @default.
• W2046269364 cites W2085106134 @default.
• W2046269364 cites W2086030126 @default.
• W2046269364 cites W2095636772 @default.
• W2046269364 cites W2097069418 @default.
• W2046269364 cites W2097384422 @default.
• W2046269364 cites W2098152992 @default.
• W2046269364 cites W2098394317 @default.
• W2046269364 cites W2106631163 @default.
• W2046269364 cites W2127689470 @default.
• W2046269364 cites W2129931005 @default.
• W2046269364 cites W2142699991 @default.
• W2046269364 cites W2143161686 @default.
• W2046269364 cites W2145291973 @default.
• W2046269364 cites W2152755402 @default.
• W2046269364 cites W2160423806 @default.
• W2046269364 cites W2161785083 @default.
• W2046269364 cites W2322140879 @default.
• W2046269364 cites W2324850882 @default.
• W2046269364 cites W2329648702 @default.
• W2046269364 cites W260508585 @default.
• W2046269364 cites W4238208852 @default.
• W2046269364 cites W80596047 @default.
• W2046269364 doi "https://doi.org/10.4161/onci.23080" @default.
• W2046269364 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3601178" @default.
• W2046269364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23525357" @default.
• W2046269364 hasPublicationYear "2013" @default.
• W2046269364 type Work @default.
• W2046269364 sameAs 2046269364 @default.
• W2046269364 citedByCount "26" @default.
• W2046269364 countsByYear W20462693642013 @default.
• W2046269364 countsByYear W20462693642014 @default.
• W2046269364 countsByYear W20462693642015 @default.
• W2046269364 countsByYear W20462693642016 @default.
• W2046269364 countsByYear W20462693642017 @default.
• W2046269364 countsByYear W20462693642018 @default.
• W2046269364 countsByYear W20462693642019 @default.
• W2046269364 countsByYear W20462693642020 @default.
• W2046269364 countsByYear W20462693642021 @default.
• W2046269364 countsByYear W20462693642022 @default.
• W2046269364 countsByYear W20462693642023 @default.
• W2046269364 crossrefType "journal-article" @default.
• W2046269364 hasAuthorship W2046269364A5000473619 @default.
• W2046269364 hasAuthorship W2046269364A5001102421 @default.
• W2046269364 hasAuthorship W2046269364A5012214419 @default.
• W2046269364 hasAuthorship W2046269364A5013335730 @default.
• W2046269364 hasAuthorship W2046269364A5013921145 @default.
• W2046269364 hasAuthorship W2046269364A5021624793 @default.
• W2046269364 hasAuthorship W2046269364A5024902665 @default.
• W2046269364 hasAuthorship W2046269364A5031362151 @default.
• W2046269364 hasAuthorship W2046269364A5039850863 @default.
• W2046269364 hasAuthorship W2046269364A5042558055 @default.
• W2046269364 hasAuthorship W2046269364A5044456322 @default.
• W2046269364 hasAuthorship W2046269364A5052579165 @default.
• W2046269364 hasAuthorship W2046269364A5056132643 @default.
• W2046269364 hasAuthorship W2046269364A5057516732 @default.
• W2046269364 hasAuthorship W2046269364A5070881504 @default.
• W2046269364 hasAuthorship W2046269364A5074612242 @default.
• W2046269364 hasBestOaLocation W20462693641 @default.
• W2046269364 hasConcept C126322002 @default.

• next